Exporting Cannabis to the UK: What Canadian LPs Need to Know in 2026

Cannabis-based products for medicinal use (CBPMs) in the UK are regulated as unlicensed "specials" unless they hold a full marketing authorisation from the MHRA. Three licensed medicines hold marketing authorisation: Sativex, Epidyolex, and Nabilone. Everything else, including imported dried flower from Canadian LPs, enters as an unlicensed CBPM under the Misuse of Drugs Regulations 2001.

In November 2018, CBPMs moved from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. That change made it legal for GMC-registered specialist physicians to prescribe them and for licensed importers to bring them in. It did not make importing straightforward. Cannabis as a plant remains Schedule 1 under the Misuse of Drugs Act 1971. That dual-classification creates compliance obligations on both the import side and the prescribing side.

Three categories of entity are authorised to procure unlicensed CBPMs in the UK:

• Specialist Importers holding both a Home Office controlled drug licence and an MHRA Wholesale Distribution Authorisation (WDA(H)).
• Manufacturers holding a Manufacturer's Specials Licence from the MHRA alongside a Home Office controlled drug licence.
• Licensed wholesalers with the appropriate controlled drug schedule coverage on their WDA(H).

For Canadian LPs, the Specialist Importer is the primary commercial and regulatory counterpart. The importer holds the UK-side licences, files the MHRA import notification, manages UK customs clearance, and places the product in quarantine pending release. The LP supplies the documentation that makes the importer's notification valid. Without a complete documentation package from the Canadian exporter, the MHRA notification cannot proceed.

One consequence of Brexit worth noting: automatic EU regulatory recognition was removed. Companies holding EMA authorisation no longer receive MHRA approval as a result. Canadian LPs are not directly affected, since Health Canada GMP was never tied to EMA pathways. EU-GMP certification from a Canadian LP is treated by the MHRA as a standalone credential.

MHRA requires a valid GMP certificate for the site of manufacture on every import notification. For Canadian LPs, this means one of two documentation routes:

Route A: EU-GMP certification

EU-GMP is the most recognised and broadly accepted standard by the MHRA. A Canadian LP holding EU-GMP certification from an accredited body can supply the certificate directly as part of the importer's notification package. No additional MHRA-specific assessment of the manufacturing standard is required.

Route B: Health Canada GMP

Health Canada's Good Production Practices (GPP) framework is aligned with pharmaceutical GMP principles and is accepted by the MHRA when supported by a current inspection certificate and complete batch manufacturing records. Supply your most recent Health Canada inspection report or a letter confirming licence standing. Include Certificates of Analysis from an ISO/IEC 17025-accredited laboratory covering cannabinoid profile, microbial limits, heavy metals, pesticide residues, and water activity.

With the LP's documentation in hand, the UK Specialist Importer follows this process:

1. The importer files the notification with the MHRA at least 28 days before the intended import date. The package includes the GMP certificate, prescriber justification from a GMC-registered specialist, product specifications, and the importer's own licences.
2. The MHRA reviews the notification during the 28-day window. If no objection is raised, the import can proceed. If the MHRA raises an objection, the shipment cannot enter.
3. The product arrives in the UK and is placed in quarantine at the Specialist Importer's licensed warehouse. Routine customs and quality checks are completed before the product is released into the supply chain.
4. The importer must maintain records of every import for at least five years, available for MHRA inspection on request.

In clinical emergencies, MHRA can grant permission before the 28-day period elapses. Canadian LPs supplying on a recurring basis should build the 28-day minimum into every supply agreement timeline. First-shipment clearance often takes longer as the MHRA reviews the manufacturing documentation for the first time.

Every shipment to the UK requires a per-shipment export permit from Health Canada under the Cannabis Act and Cannabis Regulations. Canada's obligations under the Single Convention on Narcotic Drugs, 1961 require that each shipment be individually authorised. There are no standing annual permits.

Each export permit application requires the LP to confirm:

• The export is for medical or scientific purposes only.
• The destination country (the UK) has issued a corresponding import authorisation. The UK Specialist Importer should provide the LP with a copy of their Home Office controlled drug licence to support this confirmation.
• The LP holds a valid licence in good standing with Health Canada and there are no outstanding compliance concerns.
• The quantity and product description match the importer's notification to the MHRA.

Health Canada's published service standard for export permit issuance is 20 business days from receipt of a complete application. Combined with the MHRA's 28-day notification window, the realistic lead time for a first shipment to the UK is 10 to 12 weeks from initiating the documentation process. Repeat shipments with an established UK importer move faster once both permit pathways are familiar to the parties involved.

Worth building into any supply agreement: the UK importer must provide the LP with a copy of their Home Office licence before the Canadian export permit application is filed. Canadian LPs should make this a contractual requirement in any supply agreement, with a defined timeline for the importer to supply their licence documentation. Missing or expired Home Office licence documentation is one of the most common causes of export permit delays on the Canadian side.

UK Specialist Importers evaluate Canadian suppliers on documentation readiness before committing to a supply agreement. A Canadian LP that cannot supply complete documentation at the first meeting will lose the engagement to a competitor who can. See our export packaging and labelling guide for the physical product requirements that also apply to UK shipments. UK importers expect documentation across five areas from a prospective Canadian supplier:

The Canadian LP UK Readiness Checklist

1. Current Health Canada licence confirming Standard Cultivation or Processing licence in good standing.
2. GMP certificate: EU-GMP preferred (see our EU-GMP vs Health Canada GMP comparison); Health Canada GPP inspection certificate with no outstanding observations accepted as an alternative.
3. Representative COA from a recent batch, covering the full MHRA-required analytical panel from an ISO/IEC 17025-accredited laboratory.
4. Product specifications including shelf-life data supporting at least six months from manufacture. The MHRA and UK importers require stability data to confirm product integrity through the distribution chain.
5. Confirmation of export permit eligibility: a brief written statement that the LP holds a valid Cannabis Act export authorisation and has no outstanding compliance holds with Health Canada.

AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain ISO/IEC 17025-certified batch testing, full genetic traceability, and GMP-aligned quality documentation. Our COA panel covers the complete analytical scope the MHRA requires, and our stability data supports the six-month shelf-life threshold that UK importers need to manage their distribution timelines. For UK Specialist Importers evaluating Canadian supply options, we can provide a full documentation package at the initial enquiry stage.

Can a Canadian cannabis LP export to the UK?

Yes. A Canadian LP can supply cannabis-based products for medicinal use to UK Specialist Importers. The LP needs a valid Health Canada export permit, a GMP certificate accepted by the MHRA, and batch COAs from an ISO/IEC 17025-accredited laboratory. The UK importer handles the Home Office controlled drug licence and MHRA import notification.

What GMP standard does the MHRA accept from Canadian exporters?

The MHRA requires a valid GMP certificate for the site of manufacture. EU-GMP certification is fully accepted. Health Canada GMP, recognised as equivalent to EU-GMP standards in the pharmaceutical sector, is also accepted when supported by a current inspection certificate and complete batch manufacturing records.

How does the MHRA import notification process work?

The UK Specialist Importer notifies the MHRA at least 28 days before the intended import date. The MHRA reviews the notification and may object within that window. If no objection is raised, the import can proceed. The notification must include the GMP certificate for the manufacturing site, prescriber justification from a GMC-registered specialist, and product specifications from the Canadian LP.

Does every shipment to the UK require a new Health Canada export permit?

Yes. Under the Cannabis Regulations, Health Canada issues export permits on a per-shipment basis. Each application must confirm the destination country has issued the corresponding import authorisation, the export is for medical purposes only, and the LP holds a licence in good standing. The UK importer's Home Office licence documentation supports the Canadian export permit application.

What is the size of the UK medical cannabis market in 2026?

The UK private medical cannabis market is estimated at £300 to 500 million in value as of 2026, with approximately 100,000 active private patients. NHS prescribing remains limited. Specialist cannabis clinics and licensed wholesalers serve the private sector. That channel is where commercial growth for imported CBPMs is occurring.